Assembly Biosciences, Inc. ASMB · Stock Open Assembly Biosciences, Inc. in new tab
Assembly Biosciences, Inc. Analysis (ASMB)
Is Assembly Biosciences, Inc. a good investment? Assembly Biosciences, Inc. (ASMB) is currently trading at 25.36 USD. Market analysts have a consensus price target of 50.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 317.00. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Assembly Biosciences, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.11.
Investor FAQ
Does Assembly Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Assembly Biosciences, Inc.?
Assembly Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 0.08.
Company Profile
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Split Date | Split Ratio to 1 |
|---|---|
| July 14, 2014 | 0.200000 |
| Feb. 12, 2024 | 0.080000 |
Community Discussion